SUMMARY
Background Suicidal behavior is highly heterogeneous and complex. A better understanding of its biological substrates and mechanisms could inform the design of more effective suicide prevention and intervention strategies. Neuroimaging studies of suicidality have so far been conducted in small samples, prone to biases and false-positive associations, yielding inconsistent results. The ENIGMA-MDD working group aims to address the issues of poor replicability and comparability by coordinating harmonized analyses across neuroimaging studies of major depressive disorder and related phenotypes, including suicidal behavior.
Methods Here, we pool data from eighteen international cohorts with neuroimaging and clinical measurements in 18,925 participants (12,477 healthy controls and 6,448 people with depression, of whom 694 had attempted suicide). We compare regional cortical thickness and surface area, and measures of subcortical, lateral ventricular and intracranial volumes between suicide attempters, clinical controls (non-attempters with depression) and healthy controls.
Findings We identified 25 regions of interest with statistically significant (FDR<0.05) differences between groups. Post-hoc examinations identified neuroimaging markers associated with suicide attempt over and above the effects of depression, including smaller volumes of the left and right thalamus and the right pallidum, and lower surface area of the left inferior parietal lobe.
Interpretation This study addresses the lack of replicability and consistency in several previously published neuroimaging studies of suicide attempt, and further demonstrates the need for well-powered samples and collaborative efforts to avoid reaching biased or misleading conclusions. Our results highlight the potential involvement of the thalamus, a structure viewed historically as a passive gateway in the brain, and the pallidum, a region linked to reward response and positive affect. Future functional and connectivity studies of suicidality may focus on understanding how these regions relate to the neurobiological mechanisms of suicide attempt risk.
Competing Interest Statement
Hans J. Grabe has received travel grants and speakers’ honoraria from Fresenius Medical Care, Neuraxpharm, Servier, and Janssen Cilag as well as research funding from Fresenius Medical Care; Carlos A. Zarate is a full-time U.S. government employee. He is listed as a co-inventor on a patent for the use of ketamine and its metabolites in major depression and suicidal ideation. Dr. Zarate has assigned his patent rights to the U.S. government but will share a percentage of any royalties that may be received by the government. NJ and PMT are MPI of a research related grant from Biogen, Inc., for work unrelated to this manuscript.
Funding Statement
The work reported here was supported in part by many public and private agencies across the world. Core funding for ENIGMA was provided by the NIH Big Data to Knowledge (BD2K) program under consortium grant U54 EB020403. AFFDIS was supported by the University Medical Center Göttingen and the German Federal Ministry of Education and Research (Bundesministerium fuer Bildung und Forschung, BMBF: 01 ZX 1507, “PreNeSt - e:Med”). The BiDirect study was supported by grants from the German Federal Ministry of Education and Research (BMBF; grants FKZ-01ER0816 and FKZ-01ER1506). ETPB study at NIH is funded by the National Institute of Mental Health Intramural Program. The FOR2107 study was supported by the German Research Foundation (DFG) grant Nos Ki588/14-1 and Ki588/14-2 to TK. The IMH Singapore cohort was supported by the National Healthcare Group Research Grant (SIG/15012) awarded to KS. The LOND study was supported in part by the Biomedical Research Centre, South London and Maudsley NHS Foundation Trust, London, UK. The Stanford study was supported in part by the National Institute of Mental Health Grant R37-MH101495 to IHG. The Melbourne study was supported by Australia’s National Health and Medical Research Council (NHMRC) Project Grants 1064643 (principal investigator, BJH) and 1024570 (principal investigator, CGD). The QTIM study was supported by the National Institute of Child Health and Human Development (R01-HD050735), and the National Health and Medical Research Council (NHMRC 486682, 1009064), Australia (principal investigator MJW). The Pharmo study in Amsterdam was supported by faculty resources of the Academic Medical Center, University of Amsterdam, and 11.32050.26 ERA-NET PRIOMEDCHILD FP 6 (EU). The UCSF study was funded in part by the National Institute of Mental Health (R01MH085734 and K01MH117442), National Center for Complementary and Integrative Health (NCCIH 1R61AT009864) and the American Foundation for Suicide Prevention (AFSP). The Edinburgh group is funded by a Wellcome Trust Strategic Award “Stratifying Resilience and Depression Longitudinally” (STRADL) (Reference 104036/Z/14/Z). The SHIP cohort is part of the Community Medicine Research Network of the University Medicine Greifswald, which is supported by the German Federal State of Mecklenburg- West Pomerania. AIC is supported by a UQ Research Training Scholarship from The University of Queensland (UQ). MER thanks the support of the NHMRC and Australian Research Council (ARC) through a Research Fellowship (APP1102821). BJH and CGD were supported by NHMRC Career Development Fellowships (1124472 and 1061757, respectively). SEM thanks funding support from NHMRC grants APP1103623, APP1158127, and APP1172917. TTY is funded in part by NCCIH 1R61AT009864. LS and NJ received support from the National Institute of Mental Health of the National Institutes of Health (USA) under Award Number R01-MH117601.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data and code requests will be evaluated on a case by case basis to comply with IRB policies and regulations. Interested researchers may contact the corresponding author of this study for information.
